Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03724942
Recruitment Status : Recruiting
First Posted : October 30, 2018
Last Update Posted : December 27, 2018
Sponsor:
Information provided by (Responsible Party):
Otsuka Pharmaceutical Co., Ltd.

Brief Summary:
To evaluate the safety of brexpiprazole 1 mg or 2 mg after a 14 week treatment regimen for agitation associated with dementia of the Alzheimer's type patients who completed in a double-blind trial, and to investigate the efficacy of brexpiprazole.

Condition or disease Intervention/treatment Phase
Agitation Associated With Dementia of the Alzheimer's Type Drug: Brexpiprazole Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 157 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Uncontrolled, Open-label Trial to Evaluate the Safety of Extended Treatment With Brexpiprazole (OPC-34712) to Patients With Agitation Associated With Dementia of the Alzheimer's Type
Actual Study Start Date : November 9, 2018
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2021


Arm Intervention/treatment
Experimental: Brexpiprazole Drug: Brexpiprazole
Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks
Other Name: OPC-34712




Primary Outcome Measures :
  1. The frequency of Adverse events [ Time Frame: From baseline to week 14 ]

Secondary Outcome Measures :
  1. Mean change from baseline in Cohen-Mansfield Agitation Inventory (CMAI) score at 14 weeks after dosing [ Time Frame: Baseline and 14 weeks after dosing ]
  2. Mean change from baseline in Clinical Global Impression of Severity (CGI-S) score at 14 weeks after dosing [ Time Frame: Baseline and 14 weeks after dosing ]
  3. Mean change from baseline in Clinical Global Impression of Improvement (CGI-I) score at 14 weeks after dosing [ Time Frame: Baseline and 14 weeks after dosing ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who completed the double-blind treatment period for 10 weeks and all observation, examination and evaluation at Week 10 of the double-blind trial.
  • Patients whose caregiver can properly collect the necessary information.

Exclusion Criteria:

  • Patients who had a serious adverse event which the principal investigator or sub-investigator assessed as related to the investigator product during the double-blind trial.
  • Patients who had delirium during the double-blind trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03724942


Contacts
Layout table for location contacts
Contact: Drug Information Center +81-3-6361-7314

Locations
Layout table for location information
Japan
Jisenkai Nanko Psychiatric Institute Recruiting
Shirakawa, Japan
Sponsors and Collaborators
Otsuka Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Osamu Sato Otsuka Pharmaceutical Co., Ltd.

Layout table for additonal information
Responsible Party: Otsuka Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT03724942     History of Changes
Other Study ID Numbers: 331-102-00184
First Posted: October 30, 2018    Key Record Dates
Last Update Posted: December 27, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Brexpiprazole
Dementia
Psychomotor Agitation
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Tauopathies
Neurodegenerative Diseases
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents